- Page 2 and 3:
Goodman & Gilman’sThe Pharmacolog
- Page 4 and 5:
Goodman & Gilman’sThe Pharmacolog
- Page 6 and 7:
Material from the disk that accompa
- Page 8 and 9:
This page intentionally left blank
- Page 10 and 11:
viiiCONTENTS22. Treatment of Centra
- Page 12 and 13:
This page intentionally left blank
- Page 14 and 15:
xiiCONTRIBUTORSBruce A. Chabner, MD
- Page 16 and 17:
xivCONTRIBUTORSJonathan M. Meyer, M
- Page 18 and 19:
xviCONTRIBUTORSRobert H. Tukey, PhD
- Page 20 and 21:
This page intentionally left blank
- Page 22 and 23:
This page intentionally left blank
- Page 24 and 25:
This page intentionally left blank
- Page 26 and 27:
This page intentionally left blank
- Page 28 and 29:
4SECTION IGENERAL PRINCIPLESbegan i
- Page 30 and 31:
6SECTION IGENERAL PRINCIPLESTARGETS
- Page 32 and 33:
its mission cannot possibly be acco
- Page 34 and 35:
10SECTION IGENERAL PRINCIPLESHMG-Co
- Page 36 and 37:
12SECTION IGENERAL PRINCIPLESit to
- Page 38 and 39:
14SECTION IGENERAL PRINCIPLESviolat
- Page 40 and 41:
16SECTION IGENERAL PRINCIPLESyears.
- Page 42 and 43:
18SECTION IGENERAL PRINCIPLESDRUGDO
- Page 44 and 45:
20SECTION IGENERAL PRINCIPLEScompou
- Page 46 and 47:
22SECTION IGENERAL PRINCIPLESgroups
- Page 48 and 49:
24SECTION IGENERAL PRINCIPLESphysic
- Page 50 and 51:
26SECTION IGENERAL PRINCIPLESdivers
- Page 52 and 53:
28SECTION IGENERAL PRINCIPLESphase
- Page 54 and 55:
30SECTION IGENERAL PRINCIPLESDivisi
- Page 56 and 57:
32SECTION IGENERAL PRINCIPLESconsis
- Page 58 and 59:
34SECTION IGENERAL PRINCIPLEStherap
- Page 60 and 61:
36SECTION IGENERAL PRINCIPLESMainte
- Page 62 and 63:
38SECTION IGENERAL PRINCIPLESThe ne
- Page 64 and 65:
This page intentionally left blank
- Page 66 and 67:
42 signaling compounds are termed a
- Page 68 and 69:
44 receptors, but because the endog
- Page 70 and 71:
46 ligand-receptor complex, LR*. Th
- Page 72 and 73:
48 agonist plus an effective concen
- Page 74 and 75:
50SECTION IGENERAL PRINCIPLESPRESCR
- Page 76 and 77:
52 constrained by compartmentation
- Page 78 and 79:
54A. Activation by Ligand Binding o
- Page 80 and 81:
56 Second MessengersSECTION IGENERA
- Page 82 and 83:
58 markedly stimulates Ca 2+ flux,
- Page 84 and 85:
60 voltage-gated (Jegla et al., 200
- Page 86 and 87:
62SECTION IA(a) UnligandedreceptorI
- Page 88 and 89:
64 from the complex allowing the p5
- Page 90 and 91:
66 upon binding ligand. Other membe
- Page 92 and 93:
68 FADD/TRAF2, and caspase 8, which
- Page 94 and 95:
70 of cyclic GMP are also increased
- Page 96 and 97:
72 Vo NK, Gettemy JM, Coghlan VM. I
- Page 98 and 99:
74100ADeathSECTION I% of Population
- Page 100 and 101:
76SECTION IGENERAL PRINCIPLESisofor
- Page 102 and 103:
78SECTION IGENERAL PRINCIPLESantago
- Page 104 and 105:
80SECTION IGENERAL PRINCIPLESarrhyt
- Page 106 and 107:
82SECTION IGENERAL PRINCIPLESThe in
- Page 108 and 109:
84SECTION IGENERAL PRINCIPLESGastri
- Page 110 and 111:
86SECTION IGENERAL PRINCIPLESTable
- Page 112 and 113:
This page intentionally left blank
- Page 114 and 115:
90TherapeuticeffectMetabolismTExcre
- Page 116 and 117:
92Clearance organs(liver, kidney)Co
- Page 118 and 119:
94Passive transport (downhill trans
- Page 120 and 121:
96SECTION IGENERAL PRINCIPLESNoncom
- Page 122 and 123:
Table 5-1Regulation of Transporter
- Page 124 and 125:
100ExtracellularSECTION IGENERAL PR
- Page 126 and 127:
Table 5-2Families in the Human Solu
- Page 128 and 129:
Table 5-3The ATP Binding Cassette (
- Page 130 and 131:
Table 5-4ABC Transporters Involved
- Page 132 and 133:
108SECTION IGENERAL PRINCIPLESIn th
- Page 134 and 135:
110SECTION IGENERAL PRINCIPLESthe u
- Page 136 and 137:
112SECTION IGENERAL PRINCIPLESOC +B
- Page 138 and 139:
114SECTION IGENERAL PRINCIPLEStrans
- Page 140 and 141:
116SECTION IGENERAL PRINCIPLESincre
- Page 142 and 143:
118SECTION IGENERAL PRINCIPLESHaseg
- Page 144 and 145:
120SECTION IGENERAL PRINCIPLESmulti
- Page 146 and 147:
This page intentionally left blank
- Page 148 and 149:
124SECTION IGENERAL PRINCIPLESconst
- Page 150 and 151:
126SECTION IGENERAL PRINCIPLESorall
- Page 152 and 153:
Table 6-2Major Reactions Involved i
- Page 154 and 155:
130SECTION IGENERAL PRINCIPLESco-ad
- Page 156 and 157:
132SECTION IGENERAL PRINCIPLESreact
- Page 158 and 159:
134SECTION IGENERAL PRINCIPLESSN-38
- Page 160 and 161:
136SECTION IGENERAL PRINCIPLESnon-c
- Page 162 and 163:
Table 6-4Indications and Unwanted S
- Page 164 and 165:
140SECTION IGENERAL PRINCIPLESsyndr
- Page 166 and 167:
142SECTION IGENERAL PRINCIPLESthe t
- Page 168 and 169:
This page intentionally left blank
- Page 170 and 171:
146SECTION IGENERAL PRINCIPLESstres
- Page 172 and 173:
148SECTION IGENERAL PRINCIPLESsubst
- Page 174 and 175:
150SECTION IGENERAL PRINCIPLESEthni
- Page 176 and 177:
152Monogenic traitMultigenic traitS
- Page 178 and 179:
154SECTION IGENERAL PRINCIPLESlikel
- Page 180 and 181:
15625060Common genetic formSECTION
- Page 182 and 183:
158AgeneCYP3A5*1 allele123456789101
- Page 184 and 185:
Table 7-3Examples of Genetic Polymo
- Page 186 and 187:
162warfarinCYP2C9hydroxywarfarin5SE
- Page 188 and 189:
164SECTION IGENERAL PRINCIPLESin a
- Page 190 and 191:
166SECTION IGENERAL PRINCIPLESBIBLI
- Page 192 and 193:
168SECTION IGENERAL PRINCIPLESRosne
- Page 194 and 195:
This page intentionally left blank
- Page 196 and 197:
172 regulation of sacral parasympat
- Page 198 and 199:
174 third lumbar segment. The axons
- Page 200 and 201:
176 ganglia, the ratio of pregangli
- Page 202 and 203:
Table 8-1Responses of Effector Orga
- Page 204 and 205:
Table 8-1Responses of Effector Orga
- Page 206 and 207:
182 While these criteria are applic
- Page 208 and 209:
184 those vesicles in close proximi
- Page 210 and 211:
186HemicholiniumAcCoA + CholineChol
- Page 212 and 213:
188 in transmitter release comes fr
- Page 214 and 215:
190 Subtypes of Nicotinic Acetylcho
- Page 216 and 217:
Table 8-3Characteristics of Muscari
- Page 218 and 219:
194 and inhibition of excitable mem
- Page 220 and 221:
196SECTION IINEUROPHARMACOLOGYcorre
- Page 222 and 223:
Table 8-5Characteristics of Plasma
- Page 224 and 225:
200 by activation of β 2adrenergic
- Page 226 and 227:
202SECTION IIHOHOCH 3 OHOHOHHO H OH
- Page 228 and 229:
Table 8-6Characteristics for Adrene
- Page 230 and 231:
Table 8-7Representative Agents Acti
- Page 232 and 233:
208α 1A α 2A β 1NH 2NH 2NH 2SECT
- Page 234 and 235:
210 uncoupling of G-protein signali
- Page 236 and 237:
212 and atenolol, which antagonize
- Page 238 and 239:
214 to inhibit its own release. NPY
- Page 240 and 241:
216 Furchgott RF. Endothelium-deriv
- Page 242 and 243:
218 Nucleotides as Regulators of Ce
- Page 244 and 245:
220 M 1through M 5muscarinic recept
- Page 246 and 247:
222 difficult to observe with admin
- Page 248 and 249:
224 The difficulty in developing su
- Page 250 and 251:
226 neurotransmitter release, the p
- Page 252 and 253:
228 parasympathetic postganglionic
- Page 254 and 255:
230 sympathetic cholinergic fibers,
- Page 256 and 257:
Table 9-3Muscarinic Receptor Antago
- Page 258 and 259:
234 efficient, resulting in the del
- Page 260 and 261:
236 Chapple C, Khullar V, Gabriel Z
- Page 262 and 263:
This page intentionally left blank
- Page 264 and 265:
240 In the 1950s, a series of aroma
- Page 266 and 267:
242 tertiary amine physostigmine ex
- Page 268 and 269:
Table 10-1Chemical Classification o
- Page 270 and 271:
246 The sites of action of anti- Ch
- Page 272 and 273:
248 tolerance reassessments, and re
- Page 274 and 275:
250 animals after long- term exposu
- Page 276 and 277:
252 When the diagnosis of myastheni
- Page 278 and 279:
254 Gallo MA, Lawryk NJ. Organic ph
- Page 280 and 281:
256 the inhibitory amino acids (γ-
- Page 282 and 283:
258 abundance in muscle, along with
- Page 284 and 285:
260 and the remainder of the muscle
- Page 286 and 287:
262SECTION IINEUROPHARMACOLOGYmyeli
- Page 288 and 289:
Table 11-2Classification of Neuromu
- Page 290 and 291:
266 Preventing Trauma During Electr
- Page 292 and 293:
268 reduced renal function (pancuro
- Page 294 and 295:
270 that are selective for M 1musca
- Page 296 and 297:
272 and its metabolites are elimina
- Page 298 and 299:
274 gastric emptying. Although the
- Page 300 and 301:
276 Volle RL. Nicotinic ganglion-st
- Page 302 and 303:
278Adrenergic AgonistsDirect-acting
- Page 305:
280SECTION IITable 12-1Chemical Str
- Page 308 and 309:
282 when both types of receptors ar
- Page 310 and 311:
284 falls (epinephrine reversal). A
- Page 312 and 313:
286 increase of 20-30% in oxygen co
- Page 314 and 315:
288 Therapeutic Uses and Status. NE
- Page 316 and 317:
290 may occur, particularly in pati
- Page 318 and 319:
292HONOHHNH 3 COCOOHNHC(CH 3 ) 3HOH
- Page 320 and 321:
294 agonist that has twice the pote
- Page 322 and 323:
296 these receptors is high, althou
- Page 324 and 325:
298 CNS. Amphetamine is one of the
- Page 326 and 327:
300 treatment of attention-deficit/
- Page 328 and 329:
302 syndrome and idiopathic autonom
- Page 330 and 331:
304 transient or may respond to adj
- Page 332 and 333:
306Alkylating agentCH 3OCH 2 CHNCH
- Page 334 and 335:
308 Syncopal episodes also have occ
- Page 336 and 337:
310 ingestion of tyramine-containin
- Page 338 and 339:
312OOOOHHNOOHHNOBISOPROLOLBETAXOLOL
- Page 340 and 341:
314 Billman, 2000; Brodde and Miche
- Page 342 and 343:
316 The β receptors mediate activa
- Page 344 and 345:
318 treatment for patients with all
- Page 346 and 347:
320 for an individual patient shoul
- Page 349:
322SECTION IINEUROPHARMACOLOGYTable
- Page 353:
324SECTION IINEUROPHARMACOLOGYTable
- Page 357 and 358:
326 nadolol is its relatively long
- Page 359 and 360:
328 or membrane-stabilizing activit
- Page 361 and 362:
330 and possibly papaverine-like re
- Page 363 and 364:
332 Gupta S, Wright HM. Nebivolol:
- Page 365 and 366:
This page intentionally left blank
- Page 367 and 368:
336SECTION IINEUROPHARMACOLOGYNH 2N
- Page 369:
Table 13-1Serotonin Receptor Subtyp
- Page 372 and 373:
340SECTION IINEUROPHARMACOLOGY5-HT
- Page 374 and 375:
Table 13-3Some Actions of 5-HT in t
- Page 376 and 377:
344 suppressant in the management o
- Page 378 and 379:
346HNHNSECTION IICH 2H 3 CNHSO 2 CH
- Page 380 and 381:
Table 13-6Natural and Semisynthetic
- Page 382 and 383:
350 mCPP, an active metabolite of t
- Page 384 and 385:
352 Oby AADC, the same enzyme that
- Page 386 and 387:
354ND1 receptor familyD2 receptor f
- Page 388 and 389:
356SECTION IINEUROPHARMACOLOGYMesoc
- Page 390 and 391:
358 receptor agonist and a weak D 1
- Page 392 and 393:
360 Delgado PL, Charney DS, Price L
- Page 394 and 395:
This page intentionally left blank
- Page 396 and 397:
364 system and integrate somatic an
- Page 398 and 399:
366 from the bloodstream into the b
- Page 400 and 401:
368A Ion channels α 1 subunits for
- Page 402 and 403:
Table 14-1Subtypes of Ca 2+ Channel
- Page 404 and 405:
372SECTION IINEUROPHARMACOLOGYselec
- Page 406 and 407:
374Presynapticneuron11 107Neurotran
- Page 408 and 409:
376SECTION IINEUROPHARMACOLOGYParav
- Page 410 and 411:
(including penicillin and pentylene
- Page 412 and 413:
380 (NMDA) receptors and non- NMDA
- Page 414 and 415:
Table 14-4Subtypes of Muscarinic Re
- Page 416 and 417:
384 thence to adenylyl cyclase. α
- Page 418 and 419:
386HistamineNH 2HNNSECTION IIH 1 H
- Page 420 and 421:
388β-LPHSignal peptideJP ACTH γ-L
- Page 422 and 423:
390 Oglutamate (NMDA)-mediated neur
- Page 425 and 426:
392 (e.g., ethanol) can exert relat
- Page 427 and 428:
394 Bleich S, Romer K, Wiltfang J,
- Page 429 and 430:
This page intentionally left blank
- Page 431 and 432:
398 disease, especially myocardial
- Page 433:
400SECTION IINEUROPHARMACOLOGYTable
- Page 437:
402Table 15-1Antidepressants: Chemi
- Page 441 and 442:
404SECTION IINEUROPHARMACOLOGYanoth
- Page 443 and 444:
406SECTION IINEUROPHARMACOLOGYTable
- Page 445 and 446:
408 antipsychotics are synergistic
- Page 447 and 448:
410MAO to monoaminergic nerve termi
- Page 449 and 450:
412SECTION IINEUROPHARMACOLOGYDrug
- Page 451 and 452:
414SECTION IINEUROPHARMACOLOGYreupt
- Page 453 and 454:
This page intentionally left blank
- Page 455 and 456:
418 glutamate receptor. Advances in
- Page 457 and 458:
420SECTION IINEUROPHARMACOLOGYPRESY
- Page 459 and 460:
SECTION IINEUROPHARMACOLOGY422 Schi
- Page 461:
424Table 16-1SECTION IINEUROPHARMAC
- Page 465:
426Table 16-1Chemical Structures, D
- Page 469 and 470:
428SECTION IINEUROPHARMACOLOGYantip
- Page 471 and 472:
430SECTION IINEUROPHARMACOLOGYDA re
- Page 473:
432SECTION IINEUROPHARMACOLOGYTable
- Page 477: 434SECTION IINEUROPHARMACOLOGYTable
- Page 480 and 481: 436 Absorption for most agents is q
- Page 482 and 483: 438 seen, although they are less pr
- Page 484 and 485: 440 health of the patient. Weight g
- Page 486 and 487: 442 increased risk of sudden death
- Page 488 and 489: 444 supporting data for certain anx
- Page 490 and 491: 446 treatment with both Li + and va
- Page 492 and 493: 448 therapeutic range (6-12 μg/mL)
- Page 494 and 495: 450 Li + intoxication. Li + freely
- Page 496 and 497: 452 Barten DM, Albright CF. Therape
- Page 498 and 499: 454 Mahmoud RA, Pandina GJ, Turkoz
- Page 500 and 501: This page intentionally left blank
- Page 502 and 503: 458 searches for agents with more s
- Page 504 and 505: 460 by barbiturates and volatile an
- Page 506 and 507: 462 a model in which benzodiazepine
- Page 508 and 509: Table 17-2Major Metabolic Relations
- Page 510: 466SECTION IINEUROPHARMACOLOGYTable
- Page 513 and 514: 468SECTION IINEUROPHARMACOLOGYincid
- Page 515: Table 17-4Structures, Trade Names,
- Page 518 and 519: 472SECTION IINEUROPHARMACOLOGYAbuse
- Page 520 and 521: 474SECTION IINEUROPHARMACOLOGYenzym
- Page 522 and 523: 476 Controversy in the management o
- Page 524 and 525: 478 BIBLIOGRAPHYSECTION IINEUROPHAR
- Page 526 and 527: 480 Twyman RE, Rogers CJ, Macdonald
- Page 530 and 531: Table 18-1Actions and Selectivities
- Page 532 and 533: 486SECTION IINEUROPHARMACOLOGYNocis
- Page 534 and 535: 488 the receptor selectivity of the
- Page 536 and 537: 490SECTION IINEUROPHARMACOLOGY(Sork
- Page 538 and 539: 492SECTION IINEUROPHARMACOLOGYPrefr
- Page 540 and 541: 494SECTION IINEUROPHARMACOLOGYindir
- Page 542 and 543: 496SECTION IINEUROPHARMACOLOGYreser
- Page 544: 498Table 18-2SECTION IINEUROPHARMAC
- Page 547 and 548: 500SECTION IINEUROPHARMACOLOGYaFigu
- Page 549 and 550: 502SECTION IINEUROPHARMACOLOGYreact
- Page 551 and 552: 504 may not do so with meperidine;
- Page 553 and 554: 506 The use of fentanyl and sufenta
- Page 555 and 556: 508 doses of 20-25 mg morphine give
- Page 557 and 558: 510 of psychotomimetic side effects
- Page 559 and 560: 512 syndrome in patients dependent
- Page 561 and 562: Table 18-3Epidural or Intrathecal O
- Page 563 and 564: 516 significantly (Du Pen et al., 1
- Page 565 and 566: Routes of Administration Available.
- Page 567 and 568: question the accuracy of the diagno
- Page 569 and 570: 522 Burkle H, Dunbar S, Van Aken H.
- Page 571 and 572: 524 McIntosh M, Kane K, Parratt J.
- Page 573 and 574: This page intentionally left blank
- Page 575 and 576: 528 asthmaticus with halothane and
- Page 577 and 578: Table 19-1Properties of Inhalationa
- Page 579 and 580:
532 two-pore domain channels (Patel
- Page 581:
534Table 19-2Pharmacological Proper
- Page 584 and 585:
536 suppression of the EEG (Todd et
- Page 586 and 587:
SECTION IINEUROPHARMACOLOGY538 Etom
- Page 588 and 589:
Table 19-3Some Pharmacological Effe
- Page 590 and 591:
542 and side-effect profiles. Halot
- Page 592 and 593:
544 response to reduced blood press
- Page 594 and 595:
546 nonflammable and non-explosive
- Page 596 and 597:
548 anesthesia (Rasmussen et al., 2
- Page 598 and 599:
550 few side effects. However, succ
- Page 600:
552Table 19-4SECTION IINEUROPHARMAC
- Page 603 and 604:
554 effects on different organ syst
- Page 605 and 606:
556 potential to promote absorption
- Page 607 and 608:
558 CNS. Hypercarbia depresses the
- Page 609 and 610:
560 of other gases, resulting in a
- Page 611 and 612:
562 Grounds RM, Maxwell DL, Taylor
- Page 613 and 614:
564 Taylor DR, Pijnenburg MW, Smith
- Page 615 and 616:
566H 3 CO O CH 3C NOOC O H 2 NC OC
- Page 617 and 618:
568Aβ 1 subunitα subunitNI II III
- Page 619 and 620:
Table 20-1Susceptibility to Block T
- Page 621 and 622:
572 such as methylparaben that may
- Page 623 and 624:
574 complicates evaluation of the n
- Page 625 and 626:
576 amount of cream that can be app
- Page 627 and 628:
578 successful application of spina
- Page 629 and 630:
580 intravascular injection easier
- Page 631 and 632:
582 Yarov-Yarovoy V, McPhee JC, Ids
- Page 633 and 634:
therapy. More detailed information
- Page 635 and 636:
586SECTION IINEUROPHARMACOLOGYFigur
- Page 637 and 638:
588OpenInactivatedNa + Na +vigabatr
- Page 639 and 640:
590 The cellular electrophysiologic
- Page 641 and 642:
Table 21-3Interactions of Anti-Seiz
- Page 643 and 644:
594 These effects have been observe
- Page 645 and 646:
596 Oxcarbazepine is a prodrug that
- Page 647 and 648:
598 displacement of phenytoin from
- Page 649 and 650:
600 explain lamotrigine’s actions
- Page 651 and 652:
602 Pharmacological Effects and Mec
- Page 653 and 654:
604 should not be taken lightly, be
- Page 655 and 656:
606 of women with epilepsy have bee
- Page 657 and 658:
This page intentionally left blank
- Page 659 and 660:
610 excitotoxic injury, regional va
- Page 661 and 662:
612SECTION IIPRESYNAPTIC TERMINALDi
- Page 663 and 664:
Treatment of Parkinson DiseaseCommo
- Page 665 and 666:
616 Levodopa therapy can have a dra
- Page 667 and 668:
618 of levodopa/carbidopa. The acti
- Page 669 and 670:
620 year to AD (Petersen et al., 20
- Page 671 and 672:
622 potentially vagotonic propertie
- Page 673 and 674:
624 designated IT15. It encodes a p
- Page 675 and 676:
626Extrafusalmuscle fibersUppermoto
- Page 677 and 678:
628 therapy for advanced Parkinson
- Page 679 and 680:
630 (the “proof” of an alcoholi
- Page 681 and 682:
632 methanol is taken along with et
- Page 683 and 684:
634 2006). Acutely, ethanol results
- Page 685 and 686:
636 atherogenesis (Chapter 31). Ano
- Page 687 and 688:
638 pancreatitis has been known to
- Page 689 and 690:
640 may occur with patients who app
- Page 691 and 692:
642 termed fetal alcohol effects (F
- Page 693 and 694:
644 metabolites of the drug, especi
- Page 695 and 696:
646 Lemoine P, Harousseau H, Bortey
- Page 697 and 698:
This page intentionally left blank
- Page 699 and 700:
650 an addiction. These variables c
- Page 701 and 702:
652 paucity of other options for pl
- Page 703 and 704:
654 Withdrawal signs and symptoms o
- Page 705 and 706:
656SECTION IINEUROPHARMACOLOGYA sig
- Page 707 and 708:
658SECTION IINEUROPHARMACOLOGYTable
- Page 709 and 710:
660 crosses the blood-brain barrier
- Page 711 and 712:
662 high school students has declin
- Page 713 and 714:
664 developed and tested in control
- Page 715 and 716:
666 demonstrated in humans, the cer
- Page 717 and 718:
668 Mason BJ. Acamprosate and naltr
- Page 719 and 720:
This page intentionally left blank
- Page 721 and 722:
672Glomerulus1111210139(Outer Strip
- Page 723 and 724:
674CCCCCCCCCCCCCBB1convectivesolute
- Page 725 and 726:
676 7. As water and solutes accumul
- Page 727 and 728:
Table 25-1Excretory and Renal Hemod
- Page 729 and 730:
680 However, even with a high degre
- Page 731 and 732:
682 Effects on Urinary Excretion. O
- Page 733 and 734:
684SECTION IIIMODULATION OF CARDIOV
- Page 735 and 736:
686 cardiac arrhythmias, particular
- Page 737 and 738:
Table 25-5Inhibitors of Na + -Cl -
- Page 739 and 740:
Thiazide diuretics decrease blood p
- Page 741 and 742:
692 Pentamidine and high-dose trime
- Page 743 and 744:
694ALATE DISTAL TUBULEAND COLLECTIN
- Page 745 and 746:
696 channels are expressed in IMCD.
- Page 747 and 748:
6981DIURETICSNa+ExcretionRateMABPMA
- Page 749 and 750:
700ChronicrenalfailureNephroticsynd
- Page 751 and 752:
702SECTION IIIMODULATION OF CARDIOV
- Page 753 and 754:
704SECTION IIIMODULATION OF CARDIOV
- Page 755 and 756:
706AVPAVPV 2β γα sAdenylylCyclas
- Page 757 and 758:
708 antidiuretic response to vasopr
- Page 759 and 760:
710 antidiuretic activity without i
- Page 761 and 762:
712SECTION IIIMODULATION OF CARDIOV
- Page 763 and 764:
714 Mild facial flushing and headac
- Page 765 and 766:
Table 25-9Vasopressin Receptor Anta
- Page 767 and 768:
718 Franse LV, Pahor M, Di Bari M,
- Page 769 and 770:
This page intentionally left blank
- Page 771 and 772:
722Angiotensinogen43 a.a. propeptid
- Page 773 and 774:
724AGTAng I43 amino acidpropeptideA
- Page 775 and 776:
726 in the locus p11.4 of the X chr
- Page 777 and 778:
728 state, AngII may increase, decr
- Page 779 and 780:
730 Normally, GFR is slightly reduc
- Page 781 and 782:
732SECTION IIIMODULATION OF CARDIOV
- Page 783 and 784:
734 metabolite, moexiprilat. Moexip
- Page 785 and 786:
736 effective. Once ACE inhibitors
- Page 787 and 788:
738 • ACE inhibitors may increase
- Page 789 and 790:
(75-300 mg) reductions in blood pre
- Page 791 and 792:
742 (LIFE): A randomized trial agai
- Page 793 and 794:
744 Wallukat G, Homuth V, Fischer T
- Page 795 and 796:
746Agents decreasing O 2 demandβ A
- Page 797 and 798:
Table 27-1Organic Nitrates Availabl
- Page 799 and 800:
750 consumption. An additional bene
- Page 801 and 802:
752 angina when a nitrate-free inte
- Page 803 and 804:
754 Transmucosal or Buccal Nitrogly
- Page 805 and 806:
Table 27-2Ca 2+ Channel Blockers: C
- Page 807 and 808:
758 increased modestly. After oral
- Page 809 and 810:
760 Exertional Angina. Ca 2+ channe
- Page 811 and 812:
Table 27-3Recommended Drug Therapy
- Page 813 and 814:
764 a Ca 2+ channel blocker may pro
- Page 815 and 816:
766 Hypertension is defined convent
- Page 817 and 818:
Table 27-6Hemodynamic Effects of Lo
- Page 819 and 820:
770 refractory to drugs that block
- Page 821 and 822:
772 promotes endothelial cell depen
- Page 823 and 824:
774 Methyldopa (α-methyl-3,4-dihyd
- Page 825 and 826:
776 result of the lack of sympathet
- Page 827 and 828:
778 normal renal function. However,
- Page 829 and 830:
780 expression of hypoxia-inducible
- Page 831 and 832:
782 ameliorated by a β receptor an
- Page 833 and 834:
784 Stop Hypertension (DASH) diet m
- Page 835 and 836:
786 Chaitman BR, Pepine CJ, Parker
- Page 837 and 838:
788 Pedersen ME, Cockcroft JR. What
- Page 839 and 840:
790 Congestive heart failure is the
- Page 841 and 842:
792NormalCongestivesymptomsototoxic
- Page 843 and 844:
794sympatheticstimulationBradykinin
- Page 845 and 846:
796SECTION IIIMODULATION OF CARDIOV
- Page 847 and 848:
798 counterproductive in symptomati
- Page 849 and 850:
800 CHF and may represent one mecha
- Page 851 and 852:
802 Mechanism of the Positive Inotr
- Page 853 and 854:
804 recognition of digoxin toxicity
- Page 855 and 856:
806Pressure (mm Hg)ESPVREDPVR(diast
- Page 857 and 858:
808 acid level reduction (over 24 w
- Page 859 and 860:
810 and management of end- stage CH
- Page 861 and 862:
SECTION IIIMODULATION OF CARDIOVASC
- Page 863 and 864:
This page intentionally left blank
- Page 865 and 866:
816Na +0 mV -90 mV4 mM 150 mM0 mV -
- Page 867 and 868:
818SA nodeAtriumAV nodePurkinje fib
- Page 869 and 870:
820 MECHANISMS OF CARDIACARRHYTHMIA
- Page 871 and 872:
822ADAD1accessorypathway2BEADSECTIO
- Page 873 and 874:
Table 29-2A Mechanistic Approach to
- Page 875 and 876:
826ABDecreasedphase 4slopeIncreased
- Page 877 and 878:
828 better characterized in a range
- Page 879 and 880:
830 nodal function permits a greate
- Page 881 and 882:
832 many arrhythmias than other β
- Page 883 and 884:
834 ANTI-ARRHYTHMIC DRUGSSECTION II
- Page 886:
Table 29-5Pharmacokinetic Character
- Page 889 and 890:
838 Pharmacologic Effects. Digitali
- Page 891 and 892:
840 atrial fibrillation. However, d
- Page 893 and 894:
842 fall. To avoid this distributio
- Page 895 and 896:
844SECTION IIIMODULATION OF CARDIOV
- Page 897 and 898:
846 initially tolerating antiarrhyt
- Page 899 and 900:
848 Stewart RB, Bardy GH, Greene HL
- Page 901 and 902:
850Endothelial cellsPlatelets+COX-1
- Page 903 and 904:
852 formation of a superimposed thr
- Page 905 and 906:
About 10-15 glycosaminoglycan chain
- Page 907 and 908:
856AUnfractionedheparinFactorXaPent
- Page 909 and 910:
858 For therapeutic purposes, hepar
- Page 911 and 912:
860 Bivalirudin contains the sequen
- Page 913 and 914:
862 with the functional level of pr
- Page 915 and 916:
864 inhibits platelet function. Eld
- Page 917 and 918:
866 Dabigatran etexilate is approve
- Page 919 and 920:
868 indications as aminocaproic aci
- Page 921 and 922:
870 for clopidogrel are to reduce t
- Page 923 and 924:
872 approved, ticagrelor is the fir
- Page 925 and 926:
874 has received anticoagulant or a
- Page 927 and 928:
876 Varmus H, eds. The Molecular Ba
- Page 929 and 930:
878 to as “small, dense LDL”) (
- Page 932:
880SECTION IIIMODULATION OF CARDIOV
- Page 935 and 936:
882 increasing triglyceride- and ch
- Page 937 and 938:
884 Tangier disease, a genetic diso
- Page 939 and 940:
Table 31-3Treatment Based on LDL-C
- Page 941 and 942:
Table 31-6Assessing 10-Year Risk of
- Page 943 and 944:
890SECTION IIIMODULATION OF CARDIOV
- Page 945 and 946:
Treatment of HypertriglyceridemiaTh
- Page 947 and 948:
894 Figure 31-2 along with the reac
- Page 949 and 950:
896 Due to extensive first-pass hep
- Page 951 and 952:
898 unless the patient also is taki
- Page 953 and 954:
900 Niacin is a water-soluble B-com
- Page 955 and 956:
902 Mechanism of Action. Despite ex
- Page 957 and 958:
904 diminished remnant cholesterol
- Page 959 and 960:
906 D’Agostino RB Sr, Vasan RS, P
- Page 961 and 962:
908 Prueksaritanont T, Tang C, Qiu
- Page 963 and 964:
This page intentionally left blank
- Page 965 and 966:
912 antagonists has yet emerged as
- Page 967 and 968:
914 Regulation of Mediator Release.
- Page 969 and 970:
916 of H receptor subtypes on neigh
- Page 971 and 972:
918 by H 2blockade. In asthmatic su
- Page 973 and 974:
920 et al., 2002). Thus, the develo
- Page 975 and 976:
Table 32-2Preparations and Dosage o
- Page 977 and 978:
924 Ethylenediamines (Prototype: Py
- Page 979 and 980:
926 Caution should be used in treat
- Page 981 and 982:
Table 32-3Structure of Kinin Agonis
- Page 983 and 984:
930Aminopeptidase PKininase I(Carbo
- Page 985 and 986:
932 thrombin generation following c
- Page 987 and 988:
934 Leeb-Lundberg LM, Marceau F, Mu
- Page 989 and 990:
This page intentionally left blank
- Page 991 and 992:
938SECTION IVINFLAMMATION, IMMUNOMO
- Page 993 and 994:
940SECTION IVINFLAMMATION, IMMUNOMO
- Page 995 and 996:
942 cytoprotective PGs in the GI tr
- Page 997 and 998:
of the TP (α and β), FP (A and B)
- Page 999 and 1000:
946 receptors have limited distribu
- Page 1001 and 1002:
948 dysfunctional ROMK2, also is kn
- Page 1003 and 1004:
950 inflammation by increasing endo
- Page 1005 and 1006:
952 ligands such as oxidized lipids
- Page 1007 and 1008:
954 Physiological and Pathological
- Page 1009 and 1010:
956 FitzGerald GA. Mechanisms of pl
- Page 1011 and 1012:
This page intentionally left blank
- Page 1013 and 1014:
960 face of environmental pathogens
- Page 1015 and 1016:
962 endogenous pyrogens. The initia
- Page 1017 and 1018:
964 COX-2, and thus COX-2-mediated
- Page 1019:
966SECTION IVINFLAMMATION, IMMUNOMO
- Page 1023:
968SECTION IVINFLAMMATION, IMMUNOMO
- Page 1027:
970SECTION IVTable 34-1Classificati
- Page 1030 and 1031:
972 However, low-dose aspirin is no
- Page 1032 and 1033:
974 warfarin (12-fold), glucocortic
- Page 1034 and 1035:
976 implicated in Reye’s syndrome
- Page 1036 and 1037:
978 capillary permeability during i
- Page 1038 and 1039:
980 after initiation of therapy is
- Page 1040 and 1041:
982 result of three processes. Firs
- Page 1042 and 1043:
984 Management of Acetaminophen Ove
- Page 1044 and 1045:
986 Adverse Effects. Etodolac appea
- Page 1046 and 1047:
988SECTION IVINFLAMMATION, IMMUNOMO
- Page 1048 and 1049:
990 After absorption, piroxicam is
- Page 1050 and 1051:
992 attributable to COX-2-selective
- Page 1052 and 1053:
Table 34-3Disease-Modifying Anti-Rh
- Page 1054 and 1055:
996 year, and 0.6 mg two or three t
- Page 1056 and 1057:
998 complex with both the reduced a
- Page 1058 and 1059:
1000 refractory to other drugs used
- Page 1060 and 1061:
1002 Davies NM, Anderson KE. Clinic
- Page 1062 and 1063:
1004 Solomon SD, McMurray JJ, Pfeff
- Page 1064 and 1065:
1006 the induction and maintenance
- Page 1066 and 1067:
1008 other immunosuppressive agents
- Page 1068 and 1069:
1010TCRSECTION IVINFLAMMATION, IMMU
- Page 1070 and 1071:
1012 gout, increased P-glycoprotein
- Page 1072 and 1073:
1014 common), and/or anemia (uncomm
- Page 1074 and 1075:
1016 have overcome the problems of
- Page 1076 and 1077:
1018 cyclosporine and prednisone. I
- Page 1078 and 1079:
1020 trials. Because they remain ex
- Page 1080 and 1081:
1022 with erythema nodosum leprosum
- Page 1082 and 1083:
Table 35-2Selected Immune Globulin
- Page 1084 and 1085:
agent that ameliorates auto-immune
- Page 1086 and 1087:
1028 Eisen HJ, Tuzcu EM, Dorent R,
- Page 1088 and 1089:
This page intentionally left blank
- Page 1090 and 1091:
1032AllergenDendritic cellMast cell
- Page 1092 and 1093:
1034 ROUTES OF DRUG DELIVERYTO THE
- Page 1094 and 1095:
1036NOREPINEPHRINEHO CH CH 2 NH 2HO
- Page 1096 and 1097:
1038 the treatment of asthma due to
- Page 1098 and 1099:
1040 a marked increase in the risk
- Page 1100 and 1101:
1042SECTION IVINFLAMMATION, IMMUNOM
- Page 1102 and 1103:
1044 is the first drug to demonstra
- Page 1104 and 1105:
1046 including glycopyrrolate and a
- Page 1106 and 1107:
1048Inflammatory stimulie.g. IL-1β
- Page 1108 and 1109:
1050 Routes of Administration and D
- Page 1110 and 1111:
1052 lung function than if treatmen
- Page 1112 and 1113:
1054 were not on concomitant cortic
- Page 1114 and 1115:
1056 IL-4 and IL-13, which determin
- Page 1116 and 1117:
1058 (Dicpinigaitis, 2009a). It can
- Page 1118 and 1119:
1060AEndothelial factors influencin
- Page 1120 and 1121:
1062 Clark AR. MAP kinase phosphata
- Page 1122 and 1123:
1064 Nathani N, Little MA, Kunst H,
- Page 1124 and 1125:
This page intentionally left blank
- Page 1126 and 1127:
1068 Individual growth factors then
- Page 1128 and 1129:
Table 37-1Hematopoietic Growth Fact
- Page 1130 and 1131:
1072 estimated as ~17% based on a m
- Page 1132 and 1133:
1074 reduced without a change in lo
- Page 1134 and 1135:
1076 and many other organs. In both
- Page 1136 and 1137:
1078 (IRP1 and IRP2). Double knocko
- Page 1138 and 1139:
1080SECTION IVINFLAMMATION. IMMUNOM
- Page 1140 and 1141:
1082 limits the entry of iron into
- Page 1142 and 1143:
1084 follows usual oral doses. Comm
- Page 1144 and 1145:
SECTION IVINFLAMMATION. IMMUNOMODUL
- Page 1146 and 1147:
1088 methyl group to cobalamin is e
- Page 1148 and 1149:
1090 intracellular storage proteins
- Page 1150 and 1151:
1092 neurological signs or symptoms
- Page 1152 and 1153:
1094 DIETLiverdisease and for venou
- Page 1154 and 1155:
1096 seventh days; the reticulocyte
- Page 1156 and 1157:
1098 Hoffbrand AV, Herbert V. Nutri
- Page 1158 and 1159:
This page intentionally left blank
- Page 1160 and 1161:
This page intentionally left blank
- Page 1162 and 1163:
disorders. Chapters 38 through 44 d
- Page 1164 and 1165:
Table 38-2Properties of the Protein
- Page 1166 and 1167:
1108SECTION VHORMONES AND HORMONE A
- Page 1168 and 1169:
1110AGHBGHGHPegvisomantGHRGHRGHRGHR
- Page 1170 and 1171:
1112 Clinical Manifestations of Gro
- Page 1172 and 1173:
1114 provides a highly effective al
- Page 1174 and 1175:
1116 ZORBTIVE); somatrem refers to
- Page 1176 and 1177:
1118SECTION VHORMONES AND HORMONE A
- Page 1179 and 1180:
1120 Gonadotropin production also i
- Page 1181 and 1182:
1122 to therapeutic advantage in a
- Page 1183 and 1184:
1124 detect the presence of an ecto
- Page 1185 and 1186:
1126 CLINICAL SUMMARYSECTION VHORMO
- Page 1187 and 1188:
This page intentionally left blank
- Page 1189 and 1190:
1130 important role in energy metab
- Page 1191 and 1192:
1132BasolateralmembraneApicalmembra
- Page 1193 and 1194:
Table 39-1Properties of Iodothyroni
- Page 1195 and 1196:
1136SECTION VHORMONES AND HORMONE A
- Page 1197 and 1198:
1138 whereas dairy products and fis
- Page 1199 and 1200:
1140 it is the effects of unligande
- Page 1201 and 1202:
1142 types of thyroid dysfunction,
- Page 1203 and 1204:
1144 Subclinical Hypothyroidism. Su
- Page 1205 and 1206:
1146 of patients and hence have lit
- Page 1207 and 1208:
1148 have weak anti-thyroid action
- Page 1209 and 1210:
1150 then the lower maintenance dos
- Page 1211 and 1212:
1152 cigarette smoking has been rep
- Page 1213 and 1214:
1154 Untoward Reactions. Occasional
- Page 1215 and 1216:
1156 when prolonged treatment with
- Page 1217 and 1218:
1158 Bartalena L, Marcocci C, Tanda
- Page 1219 and 1220:
1160 combination of methimazole and
- Page 1221 and 1222:
This page intentionally left blank
- Page 1223 and 1224:
1164SECTION VHORMONES AND HORMONE A
- Page 1225 and 1226:
1166 Estrogens appear to play impor
- Page 1227 and 1228:
1168AFOLLICULAR PHASELUTEAL PHASEBF
- Page 1229 and 1230:
1170 Estrogens have positive effect
- Page 1231 and 1232:
1172AERERTATAAAgonistEEGGTCAnnnTGAC
- Page 1233 and 1234:
1174 FEMRING) may be used for slow
- Page 1235 and 1236:
1176 population continues to age. O
- Page 1237 and 1238:
1178 Tamoxifen is a triphenylethyle
- Page 1239 and 1240:
1180 increase the risk of ovarian c
- Page 1241 and 1242:
1182 with the fetal adrenal glands,
- Page 1243 and 1244:
1184 Therapeutic UsesThe two most f
- Page 1245 and 1246:
1186 capacity to supply food, energ
- Page 1247 and 1248:
1188 events in women without other
- Page 1249 and 1250:
1190 is discontinued. These agents
- Page 1251 and 1252:
1192 Grumbach MM, Auchus RJ. Estrog
- Page 1253 and 1254:
1194 Van Den Bemd GJ, Kuiper GG, Po
- Page 1255 and 1256:
119621H 3 C 20H 3 C1711CH 3side cha
- Page 1257 and 1258:
1198 (Gln) 20 (Pro) 8 (Gly) 23 arom
- Page 1259 and 1260:
1200 After Completion of Puberty. W
- Page 1261 and 1262:
1202 ATestosterone Enanthateenjoyed
- Page 1263 and 1264:
1204 Side Effects. All androgens su
- Page 1265 and 1266:
1206 to dihydrotestosterone, which
- Page 1267 and 1268:
This page intentionally left blank
- Page 1269 and 1270:
1210 the role of the hypothalamus i
- Page 1271 and 1272:
1212CYP11A1HOH 3 CH 3 CH 3 C11C8B19
- Page 1273 and 1274:
1214 G q-PLC-IP 3-Ca 2+ pathway to
- Page 1275 and 1276:
of corticosteroids—one of the maj
- Page 1277 and 1278:
1218 to the nucleus. There, it inte
- Page 1279 and 1280:
1220 effect of other agents, such a
- Page 1281 and 1282:
suppression of inflammation is of e
- Page 1283 and 1284:
1224 (e.g., corticosterone) have ap
- Page 1285 and 1286:
Table 42-4Available Preparations of
- Page 1287 and 1288:
1228 and error and must be the lowe
- Page 1289 and 1290:
1230 mineralocorticoid used is flud
- Page 1291 and 1292:
1232 Ocular Diseases. Ocular pharma
- Page 1293 and 1294:
1234 and 11-deoxycortisol are measu
- Page 1295 and 1296:
This page intentionally left blank
- Page 1297 and 1298:
1238A Fasting state B Prandial stat
- Page 1299 and 1300:
1240 interplay of various nutrients
- Page 1301 and 1302:
1242SECTION VInsulinreceptorαβY-S
- Page 1303 and 1304:
Table 43-2Different Forms of Diabet
- Page 1305 and 1306:
1246 fasting. Beyond the defect in
- Page 1307 and 1308:
1248 Therapy of DiabetesSECTION VHO
- Page 1309 and 1310:
Commercial preparations of insulin
- Page 1311 and 1312:
1252 which stabilizes the insulin h
- Page 1313 and 1314:
1254 new cases of pediatric diabete
- Page 1315 and 1316:
Table 43-7Structural Formulas of th
- Page 1317 and 1318:
Nateglinide is metabolized primaril
- Page 1319 and 1320:
1260 and their specific role in the
- Page 1321 and 1322:
1262ProglucagonGRPP Glucagon IP-1 G
- Page 1323 and 1324:
1264 DPP-4 InhibitorsMechanism of A
- Page 1325 and 1326:
1266SECTION VHORMONES AND HORMONE A
- Page 1327:
1268SECTION VHORMONES AND HORMONE A
- Page 1331 and 1332:
1270 system that prevents acute hyp
- Page 1333 and 1334:
1272 Concannon P, Rich SS, Nepom GT
- Page 1335 and 1336:
This page intentionally left blank
- Page 1337 and 1338:
12761092.5Intestine:800 mg intakeBo
- Page 1339 and 1340:
1278 removed by extrarenal mechanis
- Page 1341 and 1342:
1280 response to positive or negati
- Page 1343 and 1344:
1282SECTION VHORMONES AND HORMONE A
- Page 1345 and 1346:
1284Calcitonin/katacalcin/CGRPgene5
- Page 1347 and 1348:
1286Bone lining cellsBoneOsteoclast
- Page 1349 and 1350:
1288 25-hydroxy- and 1,25-dihydroxy
- Page 1351 and 1352:
1290 deposition in bone, once a cau
- Page 1353 and 1354:
1292OHSECTION VHOOH1OHD 3alphacalci
- Page 1355 and 1356:
1294 uses of vitamin D are discover
- Page 1357 and 1358:
1296 has been supplanted largely by
- Page 1359 and 1360:
1298 cinacalcet improves outcomes s
- Page 1361 and 1362:
1300 cancer, and coronary events (c
- Page 1363 and 1364:
1302 enamel. Osteosclerosis is char
- Page 1365 and 1366:
1304 Greenspan SL, Bone HG, Ettinge
- Page 1367 and 1368:
1306 Van Cromphaut SJ, Dewerchin M,
- Page 1369 and 1370:
This page intentionally left blank
- Page 1371 and 1372:
1310GastrinMuscarinicantagonistsSEC
- Page 1373 and 1374:
1312 • enteric-coated granules su
- Page 1375 and 1376:
1314 within 1-3 hours. Absorption m
- Page 1377 and 1378:
Table 45-2Composition and Acid Neut
- Page 1379 and 1380:
1318Severity of GERDStage ISporadic
- Page 1381 and 1382:
1320 that H. pylori plays a major e
- Page 1383 and 1384:
1322 Norgard NB, Mathews KD, Wall G
- Page 1385 and 1386:
1324ORAL4ANALLM26135+ + - - -7MPCMS
- Page 1387 and 1388:
1326 Metoclopramide is available in
- Page 1389 and 1390:
1328 undigested food into the small
- Page 1391 and 1392:
The terms laxatives, cathartics, pu
- Page 1393 and 1394:
1332SECTION VIDRUGS AFFECTING GASTR
- Page 1395 and 1396:
1334 have been used as laxatives. A
- Page 1397 and 1398:
1336 sodium bicarbonate and potassi
- Page 1399 and 1400:
1338 Loperamide N-oxide, an investi
- Page 1401 and 1402:
1340 involvement in sensitization o
- Page 1403 and 1404:
HIGHERCENTERSMemory, fear,dread, an
- Page 1405 and 1406:
1344 AntihistaminesTable 46-7SECTIO
- Page 1407 and 1408:
1346 component of nausea and vomiti
- Page 1409 and 1410:
1348 options. For patients with gas
- Page 1411 and 1412:
This page intentionally left blank
- Page 1413:
1352SECTION VIDRUGS AFFECTING GASTR
- Page 1416 and 1417:
1354 mediated inflammatory processe
- Page 1418 and 1419:
1356 rapid acetylators have lower s
- Page 1420 and 1421:
1358 liver function tests also may
- Page 1422 and 1423:
1360 for the treatment of Crohn’s
- Page 1424 and 1425:
1362 Prantera C, Cottone M, Pallone
- Page 1426 and 1427:
This page intentionally left blank
- Page 1428 and 1429:
1366SECTION VIICHEMOTHERAPY OF MICR
- Page 1430 and 1431:
1368Absorption compartment (p)SECTI
- Page 1432 and 1433:
1370SECTION VIICHEMOTHERAPY OF MICR
- Page 1434 and 1435:
1372 Third, optimal microbial kill
- Page 1436 and 1437:
1374 colonization or infection by a
- Page 1438 and 1439:
1376 penicillin that resistance dev
- Page 1440 and 1441:
1378 or by subsequent transfers to
- Page 1442 and 1443:
1380 Lewis K. Riddle of biofilm res
- Page 1444 and 1445:
This page intentionally left blank
- Page 1446 and 1447:
1384 hepatocyte infection as a dorm
- Page 1448 and 1449:
Table 49-1Malarial Parasite Develop
- Page 1450 and 1451:
Table 49-2Regimens for the Preventi
- Page 1453:
1390SECTION VIICHEMOTHERAPY OF MICR
- Page 1457:
1392SECTION VIICHEMOTHERAPY OF MICR
- Page 1461:
1394SECTION VIICHEMOTHERAPY OF MICR
- Page 1464 and 1465:
1396 site. Both artesunate and arte
- Page 1466 and 1467:
1398 recent study reported an incre
- Page 1468 and 1469:
1400 The 2,4-diaminopyrimidines mor
- Page 1470 and 1471:
1402 chloroquine and pyrimethamine-
- Page 1472 and 1473:
1404 By studying the progeny of a g
- Page 1474 and 1475:
1406 Chemistry. Cinchona contains a
- Page 1476 and 1477:
1408 MefloquineSECTION VIICHEMOTHER
- Page 1478 and 1479:
1410 Therapeutic or higher doses of
- Page 1480 and 1481:
In general, dosing should be starte
- Page 1482 and 1483:
1414 For clinical classification of
- Page 1484 and 1485:
1416 Bray PG, Ward SA, O’Neill PM
- Page 1486 and 1487:
1418 Valderramos SG, Fidock DA. Tra
- Page 1488 and 1489:
1420 The organisms can be different
- Page 1490 and 1491:
1422 African (Gambian), caused by T
- Page 1492 and 1493:
1424 Isospora belli, a coccidian pa
- Page 1494 and 1495:
1426 nifurtimox used in combination
- Page 1496 and 1497:
1428 encephalopathy (the treatment-
- Page 1498 and 1499:
1430 elapse between courses. In suc
- Page 1500 and 1501:
1432 T. brucei and can be curative
- Page 1502 and 1503:
1434 whereas children have been tre
- Page 1504 and 1505:
1436 2006), where lipid-based ampho
- Page 1506 and 1507:
1438 stomatitis, chills, abdominal
- Page 1508 and 1509:
1440 surveillance study in HIV-infe
- Page 1510 and 1511:
This page intentionally left blank
- Page 1512 and 1513:
1444SECTION VIICHEMOTHERAPY OF MICR
- Page 1514 and 1515:
1446 hyperinfection. Ivermectin is
- Page 1516 and 1517:
1448 Diphyllobothrium latum. Diphyl
- Page 1518 and 1519:
1450SECTION VIICHEMOTHERAPY OF MICR
- Page 1520 and 1521:
1452 with combination therapy for 4
- Page 1522 and 1523:
1454 (Addiss and Dreyer, 2000). Exp
- Page 1524 and 1525:
1456 ivermectin (Molyneux et al., 2
- Page 1526 and 1527:
1458 bioavailability of praziquante
- Page 1528 and 1529:
1460 Dull HB, Meredith SE. The Mect
- Page 1530 and 1531:
This page intentionally left blank
- Page 1532 and 1533:
1464SECTION VIICHEMOTHERAPY OF MICR
- Page 1534 and 1535:
1466 readily than the free fraction
- Page 1536 and 1537:
1468 Aplastic Anemia. Complete supp
- Page 1538 and 1539:
1470 anti-Pneumocystis therapy in p
- Page 1540 and 1541:
1472 DNA via an ATP-dependent react
- Page 1542 and 1543:
1474 were also receiving theophylli
- Page 1544 and 1545:
1476 Centers for Disease Control an
- Page 1546 and 1547:
1478 was that of a policeman who wa
- Page 1548 and 1549:
1480AGram positiveGram negativeSECT
- Page 1550 and 1551:
1482 Classification of the Penicill
- Page 1552 and 1553:
1484 1.5 million units every 8-12 h
- Page 1554 and 1555:
1486 under controlled conditions, i
- Page 1556 and 1557:
Table 53-1Chemical Structures and M
- Page 1558 and 1559:
1490 increasingly common. Enterococ
- Page 1560 and 1561:
1492 Serum sickness varies from mil
- Page 1562 and 1563:
Table 53-2Names, Structural Formula
- Page 1564 and 1565:
Table 53-3Cephalosporin Generations
- Page 1566 and 1567:
1498 microorganisms than is the par
- Page 1568 and 1569:
1500 Imipenem. Imipenem is marketed
- Page 1570 and 1571:
1502 Brown EJ. The molecular basis
- Page 1572 and 1573:
This page intentionally left blank
- Page 1574 and 1575:
1506ACAC IAC IIAC IIIACAC IAC IIAC
- Page 1576 and 1577:
1508SECTION VIICHEMOTHERAPY OF MICR
- Page 1578 and 1579:
1510 wounds, burns, or cutaneous ul
- Page 1580 and 1581:
1512 (Knoderer et al., 2003; Rastog
- Page 1582 and 1583:
1514 of the collecting-duct epithel
- Page 1584 and 1585:
1516 vancomycin has been recommende
- Page 1586 and 1587:
1518 Prophylactic Uses. Kanamycin c
- Page 1588 and 1589:
1520 Luzzatto L, Apirion D, Schless
- Page 1590 and 1591:
Table 55-1Structural Formulas of th
- Page 1592 and 1593:
1524 Oral doses of doxycycline and
- Page 1594 and 1595:
1526 Photosensitivity. Demeclocycli
- Page 1596 and 1597:
1528 less toxic and because strains
- Page 1598 and 1599:
1530 In general, organisms are cons
- Page 1600 and 1601:
1532 failure. No dose has been esta
- Page 1602 and 1603:
1534 gastric emptying in patients w
- Page 1604 and 1605:
1536 streptogramin A, in a 30:70 ra
- Page 1606 and 1607:
1538 Indiscriminant use and overuse
- Page 1608 and 1609:
1540 Antimicrobial Activity. Vancom
- Page 1610 and 1611:
1542 because these modalities clear
- Page 1612 and 1613:
1544 dermal ulcers, the local appli
- Page 1614 and 1615:
1546 review of the published eviden
- Page 1616 and 1617:
This page intentionally left blank
- Page 1618 and 1619:
1550SECTION VIICHEMOTHERAPY OF MICR
- Page 1620 and 1621:
1552SECTION VIICHEMOTHERAPY OF MICR
- Page 1622 and 1623:
1554 Rifamycin Overdose. Rifampin o
- Page 1624 and 1625:
1556 Other products of KatG activat
- Page 1626 and 1627:
appear during the use of this drug,
- Page 1628 and 1629:
1560 ClofazimineClofazimine (LAMPRE
- Page 1630 and 1631:
1562 acid synthase II (Larsen et al
- Page 1632 and 1633:
1564 Anti-parasitic. Dapsone is als
- Page 1634 and 1635:
1566 Therapy of MAC Pulmonary Infec
- Page 1636 and 1637:
1568SECTION VIICHEMOTHERAPY OF MICR
- Page 1638 and 1639:
1570 Orenstein EW, Basu S, Shah NS,
- Page 1640 and 1641:
1572SECTION VIICHEMOTHERAPY OF MICR
- Page 1642 and 1643:
Table 57-2Pharmocokinetic Parameter
- Page 1644 and 1645:
1576 with cryptococcosis, but the c
- Page 1646 and 1647:
Table 57-6Some Additional Contraind
- Page 1648 and 1649:
1580 excretion accounts for >90% of
- Page 1650 and 1651:
1582 13 days. Posaconazole is appro
- Page 1652 and 1653:
1584 Metabolism and Excretion. Cata
- Page 1654 and 1655:
1586 and severe angioedema develop
- Page 1656 and 1657:
1588 Oxiconazole, Sulconazole, and
- Page 1658 and 1659:
1590 De Pauw BE, Donnelly JP. Proph
- Page 1660 and 1661:
This page intentionally left blank
- Page 1662 and 1663:
Table 58-1Stages of Virus Replicati
- Page 1664 and 1665:
Table 58-2Nomenclature of Antiviral
- Page 1666 and 1667:
1598HerpessimplexCytoplasmSECTION V
- Page 1668 and 1669:
1600 and adults. In children weighi
- Page 1670 and 1671:
1602 Absorption, Distribution, and
- Page 1672 and 1673:
1604 and Faulds, 1998). Inhibitory
- Page 1674 and 1675:
1606SECTION VIICHEMOTHERAPY OF MICR
- Page 1676 and 1677:
1608 amantadine or rimantadine trea
- Page 1678 and 1679:
1610 without known airway disease,
- Page 1680 and 1681:
1612 Absorption, Distribution, and
- Page 1682 and 1683:
1614SECTION VIICHEMOTHERAPY OF MICR
- Page 1684 and 1685:
1616 anti-HBV nucleosides show enha
- Page 1686 and 1687:
1618 ≥41% of patients, and reduct
- Page 1688 and 1689:
1620 De Clercq E. Clinical potentia
- Page 1690 and 1691:
1622 for cytomegalovirus retinitis
- Page 1692 and 1693:
1624 clade per se does not seem to
- Page 1694 and 1695:
1626 control but also complicates t
- Page 1696 and 1697:
1628 Failure of an antiretroviral r
- Page 1698:
1630SECTION VIICHEMOTHERAPY OF MICR
- Page 1701 and 1702:
1632 eliminated from the body prima
- Page 1703 and 1704:
1634 accumulate in the cell, and th
- Page 1705 and 1706:
1636 Carbovir, a related guanine an
- Page 1707 and 1708:
1638 atazanavir increases the tenof
- Page 1709 and 1710:
1640 generally can be avoided by se
- Page 1711 and 1712:
Table 59-3Pharmacokinetic Propertie
- Page 1713 and 1714:
1644 effective in patients who have
- Page 1715 and 1716:
1646SECTION VIINOHNH 2 NONHOOHONHNH
- Page 1718 and 1719:
1648SECTION VIICHEMOTHERAPY OF MICR
- Page 1720 and 1721:
1650 the low doses used for this pu
- Page 1722 and 1723:
1652 diarrhea, nausea, and vomiting
- Page 1724 and 1725:
1654 In treatment-naive patients re
- Page 1726 and 1727:
1656 tipranavir/ritonavir or a comp
- Page 1728 and 1729:
1658 with an intravenous dose (Dand
- Page 1730 and 1731:
1660 In each of these settings, the
- Page 1732 and 1733:
1662 Jayasekara D, Aweeka FT, Rodri
- Page 1734 and 1735:
This page intentionally left blank
- Page 1736 and 1737:
This page intentionally left blank
- Page 1738 and 1739:
Table 60-1Alkylating AgentsNONPROPR
- Page 1740 and 1741:
Table 60-4Hormones and AntagonistsN
- Page 1742 and 1743:
1672SECTION VIIICHEMOTHERAPY OF NEO
- Page 1744 and 1745:
1674 employed in traditional cytoto
- Page 1746 and 1747:
This page intentionally left blank
- Page 1748 and 1749:
1678SECTION VIIICHEMOTHERAPY OF NEO
- Page 1750 and 1751:
1680SECTION VIIICHEMOTHERAPY OF NEO
- Page 1752 and 1753:
is reversible at usual doses, but o
- Page 1754 and 1755:
1684 However, adequate hydration an
- Page 1756 and 1757:
1686 fall for >1 month after discon
- Page 1758 and 1759:
1688 platinum complexes do not form
- Page 1760 and 1761:
1690 intravenously and decline ther
- Page 1762 and 1763:
1692Pteridine ringp-aminobenzoic ac
- Page 1764 and 1765:
1694 four doses, alternating with l
- Page 1766 and 1767:
1696Fluoropyrimidine AnalogsH 3 COH
- Page 1768 and 1769:
1698 Intrahepatic arterial infusion
- Page 1770 and 1771:
1700 the liposomal formulation is i
- Page 1772 and 1773:
1702 de novo purine synthesis and a
- Page 1774 and 1775:
1704 Cladribine is considered the d
- Page 1776 and 1777:
1706 throughout the cytoplasm (expl
- Page 1778 and 1779:
1708 prior to therapy is required t
- Page 1780 and 1781:
1710 1.6 months with ixabepilone pl
- Page 1782 and 1783:
1712 The recommended dosing regimen
- Page 1784 and 1785:
1714 As discussed in “Drug Resist
- Page 1786 and 1787:
1716 compromised renal function, do
- Page 1788 and 1789:
1718 basilar infiltrates on X-ray a
- Page 1790 and 1791:
1720 double-strand DNA breaks throu
- Page 1792 and 1793:
1722 is a potent radiosensitizer as
- Page 1794 and 1795:
1724 core, allowing access for tran
- Page 1796 and 1797:
1726 resistance against anticancer
- Page 1798 and 1799:
1728 reductase activity contributes
- Page 1800 and 1801:
1730 Westerhof GR, Rijnboutt S, Sch
- Page 1802 and 1803:
1732SECTION VIIICHEMOTHERAPY OF NEO
- Page 1804 and 1805:
1734 imatinib, as a competitive CYP
- Page 1806 and 1807:
1736 Mechanism of Action. Erlotinib
- Page 1808 and 1809:
1738 ErbB1 and ErbB2 and bind to an
- Page 1810 and 1811:
1740 In colon cancer patients, colo
- Page 1812 and 1813:
1742 and rapidly interconverting no
- Page 1814 and 1815:
1744OHOcellmembraneIGF1ROther TK re
- Page 1816 and 1817:
Table 62-1Monoclonal Antibodies App
- Page 1818 and 1819:
1748 from the site targeted by ritu
- Page 1820 and 1821:
1750 good performance status and no
- Page 1822 and 1823:
1752 patients with CD33-positive ac
- Page 1824 and 1825:
This page intentionally left blank
- Page 1826 and 1827:
1756SECTION VIIICHEMOTHERAPY OF NEO
- Page 1828 and 1829:
1758ONCH 3CH 3CH 3 O CH 3NSECTION V
- Page 1830 and 1831:
1760 Steady-state concentrations ar
- Page 1832 and 1833:
1762 administered once daily for 28
- Page 1834 and 1835:
1764SECTION VIIICHEMOTHERAPY AND TA
- Page 1837 and 1838:
1766 Available Anti-Androgens. Anti
- Page 1839 and 1840:
1768 cancer in postmenopausal women
- Page 1841 and 1842:
This page intentionally left blank
- Page 1843 and 1844:
This page intentionally left blank
- Page 1845 and 1846:
1774Superior oblique muscleLevator
- Page 1847 and 1848:
1776SECTION IXSPECIAL SYSTEMS PHARM
- Page 1849 and 1850:
covered by an episcleral vascular c
- Page 1851 and 1852:
1780 Transcorneal and transconjunct
- Page 1853 and 1854:
1782 The more commonly reported inf
- Page 1855 and 1856:
Table 64-6Antifungal Agents for Oph
- Page 1857 and 1858:
Table 64-7Autonomic Drugs for Ophth
- Page 1859 and 1860:
1788 Such combinations reduce the n
- Page 1861 and 1862:
1790 subconjunctivally during the p
- Page 1863 and 1864:
1792SECTION IXSPECIAL SYSTEMS PHARM
- Page 1865 and 1866:
1794 myopia and presumed ocular his
- Page 1867 and 1868:
ACH 3CH 3C 7 10 151 H 2 C 6 C CH CH
- Page 1869 and 1870:
1798 and reduce the synthesis of ot
- Page 1871 and 1872:
1800 Fluorouracil Filtering Surgery
- Page 1873 and 1874:
This page intentionally left blank
- Page 1875 and 1876:
1804Shunt diffusionPermeationPenetr
- Page 1877 and 1878:
1806SECTION IXSPECIAL SYSTEMS PHARM
- Page 1879 and 1880:
Table 65-3Potency of Selected Topic
- Page 1881 and 1882:
Table 65-4Topical RetinoidsRECEPTOR
- Page 1883 and 1884:
1812SECTION IXSPECIAL SYSTEMS PHARM
- Page 1885 and 1886:
Table 65-6Photochemotherapy Methods
- Page 1887 and 1888:
Table 65-7Half-Life of Antihistamin
- Page 1889 and 1890:
1818SECTION IXSPECIAL SYSTEMS PHARM
- Page 1891 and 1892:
1820 CYTOTOXIC AND IMMUNOSUPPRESSIV
- Page 1893 and 1894:
1822 Tacrolimus. Tacrolimus (FK506,
- Page 1895 and 1896:
1824 An initial dosage of 50 mg/day
- Page 1897 and 1898:
1826EpidermisNon-lesional skinAntig
- Page 1899 and 1900:
evokes the same reaction on skin wi
- Page 1901 and 1902:
1830SECTION IXSPECIAL SYSTEMS PHARM
- Page 1903 and 1904:
1832 Repka-Ramirez MS, Baraniuk JN.
- Page 1905 and 1906:
1834SECTION IXTable 66-1One-Year Fa
- Page 1907 and 1908:
Table 66-2Brand Names and Formulati
- Page 1909 and 1910:
1838 sex steroid hormones; are used
- Page 1911 and 1912:
1840 Finally, some clinicians use a
- Page 1913 and 1914:
1842SECTION IXSPECIAL SYSTEMS PHARM
- Page 1915 and 1916:
1844A.Gonadotropin (IU)757575757575
- Page 1917 and 1918:
1846 In pregnant women, the placent
- Page 1919 and 1920:
1848 Although incompletely understo
- Page 1921 and 1922:
1850 cesarean section in labor indu
- Page 1923 and 1924:
1852 Olive DL. Gonadotropin-releasi
- Page 1925 and 1926:
1854SECTION IXSPECIAL SYSTEMS PHARM
- Page 1927 and 1928:
Table 67-1Examples of Important Car
- Page 1929 and 1930:
Table 67-2Chemopreventive Agents Be
- Page 1931 and 1932:
1860 Carcinogenicity. The primary c
- Page 1933 and 1934:
1862 type (ATSDR, 2007b; Levin et a
- Page 1935 and 1936:
1864BLOOD LEAD (μg/dL)Children Adu
- Page 1937 and 1938:
1866 divalent (mercuric, Hg 2+ ) an
- Page 1939 and 1940:
1868AFairbanks,AlaskaSECTION IXAleu
- Page 1941 and 1942:
1870 Skin. The skin is very sensiti
- Page 1943 and 1944:
1872 sulfate and phosphate and can
- Page 1945 and 1946:
1874 appearance of chills and fever
- Page 1947 and 1948:
1876 Absorption, Distribution, and
- Page 1949 and 1950:
1878 development of hepatocellular
- Page 1951 and 1952:
1880APPENDIX ISuperscriptionPRINCIP
- Page 1953 and 1954:
1882APPENDIX IPRINCIPLES OF PRESCRI
- Page 1955 and 1956:
1884 >750 pairs of potentially conf
- Page 1957 and 1958:
1886 if available. The USP maintain
- Page 1959 and 1960:
1888 negative impact, that the ther
- Page 1961 and 1962:
This page intentionally left blank
- Page 1963 and 1964:
1892 has been selected from the lit
- Page 1965 and 1966:
1894 To be accurate, clearances mus
- Page 1967 and 1968:
1896 sustained-release product. Ind
- Page 1969 and 1970:
1898 Because t 1/2has been the para
- Page 1972:
1900APPENDIX IIDESIGN AND OPTIMIZAT
- Page 1976:
1902APPENDIX IIDESIGN AND OPTIMIZAT
- Page 1980:
1904APPENDIX IIDESIGN AND OPTIMIZAT
- Page 1984:
1906APPENDIX IIDESIGN AND OPTIMIZAT
- Page 1988:
1908APPENDIX IIDESIGN AND OPTIMIZAT
- Page 1992:
1910APPENDIX IIDESIGN AND OPTIMIZAT
- Page 1996:
1912APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2000:
1914APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2004:
1916APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2008:
1918APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2012:
1920APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2016:
1922APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2020:
1924APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2024:
1926APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2028:
1928APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2032:
1930APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2036:
1932APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2040:
1934APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2044:
1936APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2048:
1938APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2052:
1940APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2056:
1942APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2060:
1944APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2064:
1946APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2068:
1948APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2072:
1950APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2076:
1952APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2080:
1954APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2084:
1956APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2088:
1958APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2092:
1960APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2096:
1962APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2100:
1964APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2104:
1966APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2108:
1968APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2112:
1970APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2116:
1972APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2120:
1974APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2124:
1976APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2128:
1978APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2132:
1980APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2136:
1982APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2140:
1984APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2144:
1986APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2148:
1988APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2152:
1990APPENDIX IIDESIGN AND OPTIMIZAT
- Page 2155 and 2156:
1992INDEXAcetohexamide, 1257tAcetyl
- Page 2157 and 2158:
1994INDEXAlendronate, pharmacokinet
- Page 2159 and 2160:
1996INDEXAnalgesia/analgesics (Cont
- Page 2161 and 2162:
1998INDEXAnthracyclines, 1713-1715l
- Page 2163 and 2164:
2000INDEXAntioxidants, for pulmonar
- Page 2165 and 2166:
2002INDEXAtorvastatin (Cont.):dosag
- Page 2167 and 2168:
2004INDEXBenztropine, as antidote,
- Page 2169 and 2170:
2006INDEXBortezomib (Cont.):mechani
- Page 2171 and 2172:
2008INDEXCAPOTEN (captopril), 732-7
- Page 2173 and 2174:
2010INDEXCelecoxib (Cont.):COX isof
- Page 2175 and 2176:
2012INDEXChurg-Strauss angiitis,cyc
- Page 2177 and 2178:
2014INDEXCompound 48/80, histamine
- Page 2179 and 2180:
2016INDEXCytochrome P450CYP3A4, 897
- Page 2181 and 2182:
2018INDEXDiabetes mellitus (DM) (Co
- Page 2183 and 2184:
2020INDEXDiuretics (Cont.):inhibito
- Page 2185 and 2186:
2022INDEXDYRENIUM (triamterene), 69
- Page 2187 and 2188:
2024INDEXEpidermisand cutaneous dru
- Page 2189 and 2190:
2026INDEXEtretinate (Cont.):standar
- Page 2191 and 2192:
2028INDEXFlumazenil, 468-469, 1059a
- Page 2193 and 2194:
2030INDEXGELUSIL II, 1316tGemcitabi
- Page 2195 and 2196:
2032INDEXGynecology, drug therapy i
- Page 2197 and 2198:
2034INDEXHistamine H 1receptor anta
- Page 2199 and 2200:
2036INDEXHypobetalipoproteinemia, 8
- Page 2201 and 2202:
2038INDEXInsulin (Cont.):as antidot
- Page 2203 and 2204:
2040INDEXKKallidin, 926-932, 927f[d
- Page 2205 and 2206:
2042INDEXLice, 1818-1819Lichen plan
- Page 2207 and 2208:
2044INDEXLymphoma(s), 1755drugs for
- Page 2209 and 2210:
2046INDEXMetabolism of drugs (Cont.
- Page 2211 and 2212:
2048INDEXMisuse, poisoning and, 80M
- Page 2213 and 2214:
2050INDEXMyocardial oxygen supply,p
- Page 2215 and 2216:
2052INDEXNeurotransmitters (Cont.):
- Page 2217 and 2218:
2054INDEXNorepinephrine, 287-288adv
- Page 2219 and 2220:
2056INDEXOral contraceptives (Cont.
- Page 2221 and 2222:
2058INDEXParturitioneicosanoids and
- Page 2223 and 2224:
2060INDEXPhenytoin (Cont.):hypoglyc
- Page 2225 and 2226:
2062INDEXPolymyxins, 1538-1539Polyt
- Page 2227 and 2228:
2064INDEXPropidium, 241PROPINE (epi
- Page 2229 and 2230:
2066INDEXQT interval, prologation,
- Page 2231 and 2232:
2068INDEXRenin inhibitors, direct (
- Page 2233 and 2234:
2070INDEXSalivary secretion, muscar
- Page 2235 and 2236:
2072INDEXSmooth muscleamphetamines
- Page 2237 and 2238:
2074INDEXSucralfateadverse effects
- Page 2239 and 2240:
2076INDEXTenecteplase, 866Teniposid
- Page 2241 and 2242:
2078INDEXTOLINASE (tolazamide), 125
- Page 2243 and 2244:
2080INDEXTrospium chloride, 231, 23
- Page 2245 and 2246:
2082INDEXVecuroniumcharacteristics
- Page 2247:
2084INDEXXXALATAN (latanoprost), 17